IL153428A0 - Solid valsartan pharmaceutical compositions - Google Patents

Solid valsartan pharmaceutical compositions

Info

Publication number
IL153428A0
IL153428A0 IL15342801A IL15342801A IL153428A0 IL 153428 A0 IL153428 A0 IL 153428A0 IL 15342801 A IL15342801 A IL 15342801A IL 15342801 A IL15342801 A IL 15342801A IL 153428 A0 IL153428 A0 IL 153428A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
valsartan pharmaceutical
solid valsartan
solid
compositions
Prior art date
Application number
IL15342801A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL153428A0 publication Critical patent/IL153428A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15342801A 2000-06-22 2001-06-20 Solid valsartan pharmaceutical compositions IL153428A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59968700A 2000-06-22 2000-06-22
PCT/EP2001/006983 WO2001097805A2 (en) 2000-06-22 2001-06-20 Solid valsartan pharmaceutical compositions

Publications (1)

Publication Number Publication Date
IL153428A0 true IL153428A0 (en) 2003-07-06

Family

ID=24400655

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15342801A IL153428A0 (en) 2000-06-22 2001-06-20 Solid valsartan pharmaceutical compositions
IL153428A IL153428A (en) 2000-06-22 2002-12-12 Solid Velcartan Pharmaceuticals

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL153428A IL153428A (en) 2000-06-22 2002-12-12 Solid Velcartan Pharmaceuticals

Country Status (21)

Country Link
EP (2) EP1296677A2 (https=)
JP (3) JP2003535895A (https=)
KR (2) KR100659644B1 (https=)
CN (2) CN1221256C (https=)
AU (2) AU2001285768B2 (https=)
BR (1) BR0111868A (https=)
CA (1) CA2411882C (https=)
CZ (1) CZ20024180A3 (https=)
EC (1) ECSP024389A (https=)
HK (1) HK1052868A1 (https=)
HU (1) HUP0301390A3 (https=)
IL (2) IL153428A0 (https=)
MX (1) MXPA02012683A (https=)
NO (1) NO20026123L (https=)
NZ (2) NZ522953A (https=)
PL (1) PL358290A1 (https=)
RU (1) RU2333757C2 (https=)
SG (1) SG162605A1 (https=)
SK (1) SK18062002A3 (https=)
WO (1) WO2001097805A2 (https=)
ZA (1) ZA200210359B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1304000C (zh) * 1998-12-23 2007-03-14 诺瓦提斯公司 缬沙坦在制备用于治疗肺癌的药物中的用途
NZ533968A (en) * 2002-01-17 2006-10-27 Novartis Ag Pharmaceutical compositions comprising valsartan and nep inhibitors
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
WO2005013964A1 (ja) 2003-08-08 2005-02-17 Ajinomoto Co., Inc. ナテグリニド含有製剤
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
DK2033629T3 (da) 2004-12-24 2013-02-04 Krka Fast farmaceutisk sammensætning omfattende valsartan
JP2009001520A (ja) * 2007-06-21 2009-01-08 Kowa Co ジフェンヒドラミン含有固形製剤
CN101888829A (zh) 2007-10-09 2010-11-17 诺瓦提斯公司 缬沙坦的药物制剂
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
EP2067470A1 (en) * 2007-12-03 2009-06-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing valsartan and process for its preparation
SI2536396T1 (sl) 2010-02-16 2017-01-31 KRKA, tovarna zdravil, d.d.,Novo mesto Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
CN102362865B (zh) * 2011-10-28 2013-06-26 山东司邦得制药有限公司 一种含有盐酸贝尼地平和缬沙坦的复方制剂及其应用
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
CN103599084B (zh) * 2013-11-22 2018-10-30 威海迪素制药有限公司 一种降压组合物
CN112807286A (zh) * 2021-01-20 2021-05-18 海南皇隆制药股份有限公司 一种缬沙坦分散片制备方法和缬沙坦分散片
CN112826806A (zh) * 2021-01-20 2021-05-25 海南皇隆制药股份有限公司 一种缬沙坦片制备方法和缬沙坦片
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000050I1 (de) * 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
HUT76542A (en) * 1994-03-17 1997-09-29 Ciba Geigy Ag Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy
AU725689B2 (en) * 1995-06-07 2000-10-19 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of congestive heart failure
AU7213296A (en) * 1995-10-06 1997-04-30 Ciba-Geigy Ag At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
DK0883401T3 (da) * 1996-02-29 2003-05-05 Novartis Ag AT1-receptorantagonist til stimulering af apoptose
WO1997044014A1 (en) * 1996-05-20 1997-11-27 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
CN1304000C (zh) * 1998-12-23 2007-03-14 诺瓦提斯公司 缬沙坦在制备用于治疗肺癌的药物中的用途
CN1440283A (zh) * 2000-04-12 2003-09-03 诺瓦提斯公司 有机化合物的联合形式

Also Published As

Publication number Publication date
HK1052868A1 (zh) 2003-10-03
NO20026123L (no) 2003-02-18
EP2072049A3 (en) 2009-12-30
EP2072049A2 (en) 2009-06-24
EP1296677A2 (en) 2003-04-02
HK1083452A1 (zh) 2006-07-07
CN100450478C (zh) 2009-01-14
CN1221256C (zh) 2005-10-05
KR20050085978A (ko) 2005-08-29
JP2012211200A (ja) 2012-11-01
NO20026123D0 (no) 2002-12-19
JP2003535895A (ja) 2003-12-02
SK18062002A3 (sk) 2003-07-01
ZA200210359B (en) 2003-11-13
AU2001285768B2 (en) 2005-03-10
IL153428A (en) 2013-12-31
AU8576801A (en) 2002-01-02
CA2411882C (en) 2011-09-06
BR0111868A (pt) 2003-07-01
CA2411882A1 (en) 2001-12-27
CN1679551A (zh) 2005-10-12
RU2333757C2 (ru) 2008-09-20
CN1437469A (zh) 2003-08-20
KR100659644B1 (ko) 2006-12-21
PL358290A1 (en) 2004-08-09
NZ522953A (en) 2005-10-28
NZ540748A (en) 2007-04-27
WO2001097805A2 (en) 2001-12-27
WO2001097805A3 (en) 2002-08-29
ECSP024389A (es) 2003-02-06
KR100525341B1 (ko) 2005-11-02
HUP0301390A2 (hu) 2003-11-28
HUP0301390A3 (en) 2005-04-28
SG162605A1 (en) 2010-07-29
JP2007091758A (ja) 2007-04-12
CZ20024180A3 (cs) 2003-04-16
KR20030019450A (ko) 2003-03-06
MXPA02012683A (es) 2003-04-25

Similar Documents

Publication Publication Date Title
GB2358582B (en) Pharmaceutical compositions
HUP0300582A3 (en) Pharmaceutical compositions
AU6219601A (en) Pharmaceutical compositions
EG24357A (en) New Pharmaceutical composition
IL152659A0 (en) Pharmaceutical composition
SI1524266T1 (sl) Farmacevtski sestavek
HUP0204555A3 (en) Pharmaceutical composition
AU2001250420A1 (en) Pharmaceutical compositions
GB0009584D0 (en) Pharmaceutical compositions
IL153428A0 (en) Solid valsartan pharmaceutical compositions
HUP0400553A3 (en) Pharmaceutical compositions
AU1390002A (en) Pharmaceutical compositions
GB0008485D0 (en) Pharmaceutical compositions
GB0009613D0 (en) Pharmaceutical compositions
GB0005382D0 (en) Pharmaceutical composition
AU8254101A (en) Medicinal compositions
GB0101094D0 (en) Pharmaceutical composition
GB0002691D0 (en) Pharmaceutical composition
HU0700204D0 (en) Pharmaceutical compositions
GB0008872D0 (en) Pharmaceutical compositions
GB0001337D0 (en) Pharmaceutical compositions
GB0031288D0 (en) Pharmaceutical compositions
GB0031282D0 (en) Pharmaceutical compositions
GB0018321D0 (en) Pharmaceutical compositions
GB0000062D0 (en) Pharmaceutical compositions